Information Provided By: 
Fly News Breaks for January 31, 2020
GBT
Jan 31, 2020 | 07:06 EDT
SunTrust analyst Joon Lee downgraded Global Blood Therapeutics to Hold from Buy with a price target of $75, down from $110. The analyst remains positive on the drug profile of the company's Oxbryta but sees "lower hanging fruit" as it enters the drug's launch phase "in earnest", pointing to the challenges that include payor negotiations, relatively high discontinuation rates, and near term competitive threats.
News For GBT From the Last 2 Days
There are no results for your query GBT
